Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
Quick Look: Industry players worry that political conditions are becoming less favorable for overturning off-year drug price revisions as power in the Diet consolidates. The return of policy-savvy lawmakers is lifting hopes for a pro-innovation path, but advocacy might now…
To read the full story
Related Article
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
BUSINESS
- Kyorin Starts Pivotal Study of Chronic Cough DTx in Japan
June 12, 2026
- Lotte Biopharma CVC Invests in Swiss ADC Startup
June 12, 2026
- Ono Seeks Velexbru Nod for CNS Involvement of Malignant Lymphoma
June 12, 2026
- Ono Files Opdivo for Anaplastic Thyroid Cancer
June 12, 2026
- Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…